FindTrial
Sign In

Effects of ashwagandha in advanced cancer patients

Effects of Withania sominifera in stage IV cancer patients - CANASH TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/05/003688
Enrollment
50
Registered
2013-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 50 hemodynamically stable stage IV cancer patients with or without chemotherapy shall be given the coded trial medicine or placebo

Interventions

Intervention1: Withania Somnifera (WS): After obtaining informed consent-patients shall be randomly divided into four groups. 500 mg WS and matched placebo shall be given four times a day for 6 months

Sponsors

Vir Chandra Singh Garhwali Government Institute of Medical Sciences and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient admitted in oncology ward or OPD patients of Base Hospital, Srikot, Pauri-Garhwal, Uttarakhand for chemotherapy or palliation 2. Stage IV clinically and heamodynamically stable, cancer patient willing to participate and give informed consent in the trial 3. Age group:18-60 yrs 4. Either gender

Exclusion criteria

Exclusion criteria: 1. Age 60 yrs 2. Stage I,II,III cancer patients 3. Clinically and heamodynamically unstable patients 4. Patients receiving any other alternative therapies(ayurveda/homeopathic/herbal/dietary suppliments) 5. Patient receiving G-CSF 6. Patient receiving radiotherapy 7. Acute medical or surgical complications that require hospitalization

Design outcomes

Primary

MeasureTime frame
The primary objective will be 30% improvement in QALY score after giving the trial medicine.Timepoint: The trial shall complete in one year 6months-data collection 2months-data compilation 2months-preparation of report 2months-follow up of patients and modifications if necessary—

Secondary

MeasureTime frame
To assess any survival advantage if any for patients being given WS or placebo by comparing with Historical dataTimepoint: 1year: 2 months for patient recruitment 6 months for data collection 2 months for data compliation 2 preparation of report and submission of manuscript to a national or international journal.—

Countries

India

Contacts

Public ContactDr Aditi Chaturvedi

Vir Chandra Singh Garhwali Government Institute of Medical Sciences and Research

aditichaturvedi150@yahoo.com9410507009

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026